Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOS2 | P35228 | 1/20 | 0.35 |
| ▸ | PHGDH | O43175 | 1/20 | 0.34 |
| ▸ | MGLL | Q99685 | 1/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | APOBEC3G | Q9HC16 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL467970 | 0.85 | — | — | |
| SCHEMBL13634277 | 0.84 | — | — | |
| SCHEMBL1728406 | 0.73 | — | — | |
| SCHEMBL1127536 | 0.73 | — | — | |
| SCHEMBL1690354 | 0.72 | SMN1; SMN2 (0.46) | NOS2KDM4EMAPT | |
| SCHEMBL14942478 | 0.72 | NOS2 (0.72) | NOS2 | |
| SCHEMBL14082057 | 0.72 | NOS2 (0.72) | NOS2 | |
| SCHEMBL13363702 | 0.72 | SMN1; SMN2 (0.46) | NOS2KDM4EMAPT | |
| SCHEMBL2215054 | 0.72 | SMN1; SMN2 (0.46) | NOS2KDM4EMAPT | |
| SCHEMBL9604516 | 0.71 | MGLL (0.50) | NOS2PHGDHMGLLKDM4EMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9695163-B2 | Thiazole orexin receptor antagonists | MERCK SHARP & DOHME CORP (US) | 2017-07-04 | — | — | US | disclosed |
| US-20160185768-A1 | THIAZOLE OREXIN RECEPTOR ANTAGONISTS | MERCK SHARP & DOHME CORP. (US) | 2016-06-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160185768-A1 | THIAZOLE OREXIN RECEPTOR ANTAGONISTS | HCRTR2, HCRTR1, OXTR | NOS2 3364/4885PHGDH 3544/4885MGLL 2826/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.